WEBVTT
Kind: captions
Language: en

00:00:00.030 --> 00:00:02.419 

immunotherapy<00:00:00.900> treatment<00:00:01.560> that<00:00:01.770> uses<00:00:02.010> for

00:00:02.419 --> 00:00:02.429 
immunotherapy treatment that uses for

00:00:02.429 --> 00:00:04.690 
immunotherapy treatment that uses for
the<00:00:02.520> immune<00:00:02.909> system<00:00:03.419> to<00:00:03.720> target<00:00:04.259> cells

00:00:04.690 --> 00:00:04.700 
the immune system to target cells

00:00:04.700 --> 00:00:07.789 
the immune system to target cells
rituximab<00:00:05.700> or<00:00:06.089> Rituxan<00:00:06.930> was<00:00:07.290> the<00:00:07.500> first

00:00:07.789 --> 00:00:07.799 
rituximab or Rituxan was the first

00:00:07.799 --> 00:00:10.850 
rituximab or Rituxan was the first
unlabeled<00:00:08.610> humanized<00:00:09.240> monoclonal<00:00:09.860> antibody

00:00:10.850 --> 00:00:10.860 
unlabeled humanized monoclonal antibody

00:00:10.860 --> 00:00:13.299 
unlabeled humanized monoclonal antibody
approved<00:00:11.550> for<00:00:11.940> the<00:00:12.059> treatment<00:00:12.090> of<00:00:12.570> cancer

00:00:13.299 --> 00:00:13.309 
approved for the treatment of cancer

00:00:13.309 --> 00:00:16.070 
approved for the treatment of cancer
Rituxan<00:00:14.309> recognizes<00:00:15.179> a<00:00:15.210> specific

00:00:16.070 --> 00:00:16.080 
Rituxan recognizes a specific

00:00:16.080 --> 00:00:19.490 
Rituxan recognizes a specific
glycoprotein<00:00:17.029> cd20<00:00:18.029> that<00:00:18.630> is<00:00:18.779> found<00:00:19.050> on<00:00:19.320> the

00:00:19.490 --> 00:00:19.500 
glycoprotein cd20 that is found on the

00:00:19.500 --> 00:00:22.160 
glycoprotein cd20 that is found on the
cell<00:00:19.740> membrane<00:00:20.340> of<00:00:20.369> mature<00:00:20.939> normal<00:00:21.660> b-cells

00:00:22.160 --> 00:00:22.170 
cell membrane of mature normal b-cells

00:00:22.170 --> 00:00:24.830 
cell membrane of mature normal b-cells
in<00:00:22.410> the<00:00:22.560> body<00:00:22.740> and<00:00:22.980> often<00:00:23.490> over<00:00:24.029> expressed<00:00:24.570> and

00:00:24.830 --> 00:00:24.840 
in the body and often over expressed and

00:00:24.840 --> 00:00:28.759 
in the body and often over expressed and
malignant<00:00:25.710> b-cell<00:00:26.160> lymphomas<00:00:27.199> when<00:00:28.199> Rituxan

00:00:28.759 --> 00:00:28.769 
malignant b-cell lymphomas when Rituxan

00:00:28.769 --> 00:00:31.970 
malignant b-cell lymphomas when Rituxan
binds<00:00:29.039> the<00:00:29.460> cd20<00:00:30.179> the<00:00:30.420> antibody<00:00:30.900> and<00:00:31.260> antigen

00:00:31.970 --> 00:00:31.980 
binds the cd20 the antibody and antigen

00:00:31.980 --> 00:00:34.760 
binds the cd20 the antibody and antigen
complex<00:00:32.550> starts<00:00:33.090> one<00:00:33.390> of<00:00:33.420> three<00:00:33.899> cell<00:00:34.380> lysis

00:00:34.760 --> 00:00:34.770 
complex starts one of three cell lysis

00:00:34.770 --> 00:00:37.340 
complex starts one of three cell lysis
processes<00:00:35.780> complement<00:00:36.780> dependent

00:00:37.340 --> 00:00:37.350 
processes complement dependent

00:00:37.350 --> 00:00:39.790 
processes complement dependent
cytotoxicity<00:00:38.510> antibody<00:00:39.510> dependent

00:00:39.790 --> 00:00:39.800 
cytotoxicity antibody dependent

00:00:39.800 --> 00:00:43.400 
cytotoxicity antibody dependent
cell-mediated<00:00:40.969> cytotoxicity<00:00:41.969> or<00:00:42.410> apoptosis

00:00:43.400 --> 00:00:43.410 
cell-mediated cytotoxicity or apoptosis

00:00:43.410 --> 00:00:47.569 
cell-mediated cytotoxicity or apoptosis
in<00:00:44.899> complement<00:00:45.899> dependent<00:00:46.440> cytotoxicity<00:00:47.190> or

00:00:47.569 --> 00:00:47.579 
in complement dependent cytotoxicity or

00:00:47.579 --> 00:00:51.229 
in complement dependent cytotoxicity or
CDC<00:00:48.090> the<00:00:48.930> antibody<00:00:49.410> and<00:00:49.739> antigen<00:00:50.430> complex<00:00:50.969> of

00:00:51.229 --> 00:00:51.239 
CDC the antibody and antigen complex of

00:00:51.239 --> 00:00:53.810 
CDC the antibody and antigen complex of
Rituxan<00:00:51.989> to<00:00:52.170> cd20<00:00:52.890> leads<00:00:53.430> to<00:00:53.699> the<00:00:53.789> activation

00:00:53.810 --> 00:00:53.820 
Rituxan to cd20 leads to the activation

00:00:53.820 --> 00:00:57.260 
Rituxan to cd20 leads to the activation
of<00:00:54.660> a<00:00:54.840> complement<00:00:55.500> system<00:00:55.969> part<00:00:56.969> of<00:00:57.059> the

00:00:57.260 --> 00:00:57.270 
of a complement system part of the

00:00:57.270 --> 00:00:59.540 
of a complement system part of the
innate<00:00:57.660> immune<00:00:57.840> system<00:00:58.410> the<00:00:58.949> complement

00:00:59.540 --> 00:00:59.550 
innate immune system the complement

00:00:59.550 --> 00:01:01.760 
innate immune system the complement
system<00:00:59.780> represents<00:01:00.780> a<00:01:00.899> large<00:01:01.199> group<00:01:01.620> of

00:01:01.760 --> 00:01:01.770 
system represents a large group of

00:01:01.770 --> 00:01:03.910 
system represents a large group of
proteins<00:01:02.309> that<00:01:02.520> work<00:01:02.940> together<00:01:03.180> to<00:01:03.719> destroy

00:01:03.910 --> 00:01:03.920 
proteins that work together to destroy

00:01:03.920 --> 00:01:06.560 
proteins that work together to destroy
invading<00:01:04.920> pathogens<00:01:05.580> or<00:01:05.880> cells<00:01:06.240> infected

00:01:06.560 --> 00:01:06.570 
invading pathogens or cells infected

00:01:06.570 --> 00:01:09.380 
invading pathogens or cells infected
with<00:01:07.229> pathogens<00:01:07.470> in<00:01:08.100> the<00:01:08.130> body<00:01:08.430> by<00:01:08.939> punching

00:01:09.380 --> 00:01:09.390 
with pathogens in the body by punching

00:01:09.390 --> 00:01:11.960 
with pathogens in the body by punching
holes<00:01:09.630> in<00:01:10.049> their<00:01:10.200> cell<00:01:10.470> membranes<00:01:10.970> destroying

00:01:11.960 --> 00:01:11.970 
holes in their cell membranes destroying

00:01:11.970 --> 00:01:13.850 
holes in their cell membranes destroying
the<00:01:12.210> integrity<00:01:12.540> of<00:01:12.810> the<00:01:13.020> cell<00:01:13.200> membrane<00:01:13.229> and

00:01:13.850 --> 00:01:13.860 
the integrity of the cell membrane and

00:01:13.860 --> 00:01:17.330 
the integrity of the cell membrane and
killing<00:01:14.520> the<00:01:14.670> cell<00:01:14.880> in<00:01:16.040> antibody<00:01:17.040> dependent

00:01:17.330 --> 00:01:17.340 
killing the cell in antibody dependent

00:01:17.340 --> 00:01:21.800 
killing the cell in antibody dependent
cell-mediated<00:01:18.259> cytotoxicity<00:01:19.259> or<00:01:19.850> ADCC<00:01:20.850> the

00:01:21.800 --> 00:01:21.810 
cell-mediated cytotoxicity or ADCC the

00:01:21.810 --> 00:01:24.859 
cell-mediated cytotoxicity or ADCC the
antibody<00:01:22.290> antigen<00:01:22.890> complex<00:01:23.820> of<00:01:24.060> Rituxan<00:01:24.720> to

00:01:24.859 --> 00:01:24.869 
antibody antigen complex of Rituxan to

00:01:24.869 --> 00:01:27.830 
antibody antigen complex of Rituxan to
cd20<00:01:25.560> leads<00:01:25.950> to<00:01:26.250> the<00:01:26.400> recruitment<00:01:26.850> of<00:01:27.119> natural

00:01:27.830 --> 00:01:27.840 
cd20 leads to the recruitment of natural

00:01:27.840 --> 00:01:30.170 
cd20 leads to the recruitment of natural
killer<00:01:28.080> cells<00:01:28.530> T<00:01:29.040> cells<00:01:29.070> and<00:01:29.640> macrophages

00:01:30.170 --> 00:01:30.180 
killer cells T cells and macrophages

00:01:30.180 --> 00:01:32.929 
killer cells T cells and macrophages
that<00:01:30.930> recognize<00:01:31.500> and<00:01:31.860> bind<00:01:32.100> to<00:01:32.310> Rituxan

00:01:32.929 --> 00:01:32.939 
that recognize and bind to Rituxan

00:01:32.939 --> 00:01:36.740 
that recognize and bind to Rituxan
complex<00:01:33.630> to<00:01:33.900> cd20<00:01:35.119> after<00:01:36.119> the<00:01:36.210> Lecco<00:01:36.420> sites

00:01:36.740 --> 00:01:36.750 
complex to cd20 after the Lecco sites

00:01:36.750 --> 00:01:39.890 
complex to cd20 after the Lecco sites
bind<00:01:37.110> to<00:01:37.320> Rituxan<00:01:38.030> cytotoxic<00:01:39.030> granules<00:01:39.630> are

00:01:39.890 --> 00:01:39.900 
bind to Rituxan cytotoxic granules are

00:01:39.900 --> 00:01:41.810 
bind to Rituxan cytotoxic granules are
released<00:01:40.320> and<00:01:40.590> penetrate<00:01:41.189> the<00:01:41.400> B<00:01:41.549> cell

00:01:41.810 --> 00:01:41.820 
released and penetrate the B cell

00:01:41.820 --> 00:01:44.749 
released and penetrate the B cell
membrane<00:01:42.360> some<00:01:43.020> creating<00:01:43.619> pores<00:01:43.979> to<00:01:44.490> flood

00:01:44.749 --> 00:01:44.759 
membrane some creating pores to flood

00:01:44.759 --> 00:01:46.850 
membrane some creating pores to flood
the<00:01:44.939> cell<00:01:45.210> and<00:01:45.450> some<00:01:45.960> targeting<00:01:46.470> the<00:01:46.619> cell's

00:01:46.850 --> 00:01:46.860 
the cell and some targeting the cell's

00:01:46.860 --> 00:01:49.670 
the cell and some targeting the cell's
nucleus<00:01:47.009> and<00:01:47.670> destroying<00:01:48.450> it<00:01:48.750> either<00:01:49.320> process

00:01:49.670 --> 00:01:49.680 
nucleus and destroying it either process

00:01:49.680 --> 00:01:52.660 
nucleus and destroying it either process
results<00:01:50.490> in<00:01:50.579> the<00:01:50.729> death<00:01:50.909> of<00:01:51.180> the<00:01:51.390> B<00:01:51.509> cell

00:01:52.660 --> 00:01:52.670 
results in the death of the B cell

00:01:52.670 --> 00:01:56.420 
results in the death of the B cell
apoptosis<00:01:53.670> or<00:01:54.329> programmed<00:01:54.829> cellular<00:01:55.829> suicide

00:01:56.420 --> 00:01:56.430 
apoptosis or programmed cellular suicide

00:01:56.430 --> 00:01:58.789 
apoptosis or programmed cellular suicide
can<00:01:56.909> also<00:01:57.060> occur<00:01:57.540> from<00:01:57.869> the<00:01:58.079> antibody<00:01:58.560> and

00:01:58.789 --> 00:01:58.799 
can also occur from the antibody and

00:01:58.799 --> 00:02:02.389 
can also occur from the antibody and
antigen<00:01:59.189> complex<00:01:59.700> of<00:01:59.880> Rituxan<00:02:00.780> to<00:02:00.930> cd20<00:02:01.560> this

00:02:02.389 --> 00:02:02.399 
antigen complex of Rituxan to cd20 this

00:02:02.399 --> 00:02:04.700 
antigen complex of Rituxan to cd20 this
complex<00:02:02.880> signals<00:02:03.540> the<00:02:03.719> cell<00:02:03.990> to<00:02:04.259> start<00:02:04.560> the

00:02:04.700 --> 00:02:04.710 
complex signals the cell to start the

00:02:04.710 --> 00:02:07.730 
complex signals the cell to start the
process<00:02:05.189> of<00:02:05.310> apoptosis<00:02:05.750> which<00:02:06.750> includes<00:02:07.259> cell

00:02:07.730 --> 00:02:07.740 
process of apoptosis which includes cell

00:02:07.740 --> 00:02:10.969 
process of apoptosis which includes cell
shrinkage<00:02:08.280> nucleus<00:02:09.179> fragmentation<00:02:10.110> DNA

00:02:10.969 --> 00:02:10.979 
shrinkage nucleus fragmentation DNA

00:02:10.979 --> 00:02:15.039 
shrinkage nucleus fragmentation DNA
fragmentation<00:02:11.760> and<00:02:12.090> finally<00:02:12.840> cell

00:02:15.039 --> 00:02:15.049 
fragmentation and finally cell

00:02:15.049 --> 00:02:18.110 
fragmentation and finally cell
because<00:02:16.049> cd20<00:02:16.739> is<00:02:16.890> found<00:02:17.159> on<00:02:17.340> the<00:02:17.519> surface<00:02:17.909> of

00:02:18.110 --> 00:02:18.120 
because cd20 is found on the surface of

00:02:18.120 --> 00:02:21.170 
because cd20 is found on the surface of
mature<00:02:18.569> normal<00:02:19.079> and<00:02:19.530> malignant<00:02:20.159> b-cells<00:02:20.670> both

00:02:21.170 --> 00:02:21.180 
mature normal and malignant b-cells both

00:02:21.180 --> 00:02:23.660 
mature normal and malignant b-cells both
will<00:02:21.510> be<00:02:21.599> targeted<00:02:22.079> without<00:02:22.859> the<00:02:23.040> cd20

00:02:23.660 --> 00:02:23.670 
will be targeted without the cd20

00:02:23.670 --> 00:02:26.509 
will be targeted without the cd20
receptor<00:02:24.180> in<00:02:24.329> mature<00:02:25.049> lymphoid<00:02:25.709> stem<00:02:26.069> cells

00:02:26.509 --> 00:02:26.519 
receptor in mature lymphoid stem cells

00:02:26.519 --> 00:02:28.699 
receptor in mature lymphoid stem cells
will<00:02:26.849> not<00:02:27.060> be<00:02:27.239> targeted<00:02:27.540> and<00:02:27.900> will<00:02:28.290> replace

00:02:28.699 --> 00:02:28.709 
will not be targeted and will replace

00:02:28.709 --> 00:02:30.830 
will not be targeted and will replace
the<00:02:28.980> number<00:02:29.280> of<00:02:29.400> destroyed<00:02:29.819> normal<00:02:30.359> b-cells

00:02:30.830 --> 00:02:30.840 
the number of destroyed normal b-cells

00:02:30.840 --> 00:02:32.949 
the number of destroyed normal b-cells
with<00:02:31.260> healthy<00:02:31.799> cells

00:02:32.949 --> 00:02:32.959 
with healthy cells

00:02:32.959 --> 00:02:35.780 
with healthy cells
despite<00:02:33.959> the<00:02:34.079> utility<00:02:34.590> of<00:02:34.620> Rituxan<00:02:35.280> and<00:02:35.489> its

00:02:35.780 --> 00:02:35.790 
despite the utility of Rituxan and its

00:02:35.790 --> 00:02:38.929 
despite the utility of Rituxan and its
ability<00:02:36.090> to<00:02:36.329> target<00:02:36.750> cd20<00:02:37.670> limitations<00:02:38.670> of

00:02:38.929 --> 00:02:38.939 
ability to target cd20 limitations of

00:02:38.939 --> 00:02:42.170 
ability to target cd20 limitations of
its<00:02:39.120> effectiveness<00:02:39.719> do<00:02:40.230> exist<00:02:41.180> limitations

00:02:42.170 --> 00:02:42.180 
its effectiveness do exist limitations

00:02:42.180 --> 00:02:44.690 
its effectiveness do exist limitations
such<00:02:42.569> as<00:02:42.599> malignant<00:02:43.349> cells<00:02:43.829> resistance

00:02:44.690 --> 00:02:44.700 
such as malignant cells resistance

00:02:44.700 --> 00:02:47.539 
such as malignant cells resistance
mechanisms<00:02:45.389> to<00:02:45.599> apoptosis<00:02:46.549> inadequate

00:02:47.539 --> 00:02:47.549 
mechanisms to apoptosis inadequate

00:02:47.549 --> 00:02:50.089 
mechanisms to apoptosis inadequate
immune<00:02:47.909> cell<00:02:48.239> effector<00:02:48.930> molecules<00:02:49.500> making

00:02:50.089 --> 00:02:50.099 
immune cell effector molecules making

00:02:50.099 --> 00:02:52.149 
immune cell effector molecules making
antibody<00:02:50.639> dependent<00:02:50.909> cell-mediated

00:02:52.149 --> 00:02:52.159 
antibody dependent cell-mediated

00:02:52.159 --> 00:02:55.220 
antibody dependent cell-mediated
cytotoxicity<00:02:53.159> less<00:02:53.669> effective<00:02:54.209> and<00:02:54.419> lastly

00:02:55.220 --> 00:02:55.230 
cytotoxicity less effective and lastly

00:02:55.230 --> 00:02:57.500 
cytotoxicity less effective and lastly
the<00:02:55.560> sheer<00:02:55.859> number<00:02:56.310> of<00:02:56.340> cells<00:02:56.790> that<00:02:57.120> must<00:02:57.419> be

00:02:57.500 --> 00:02:57.510 
the sheer number of cells that must be

00:02:57.510 --> 00:03:00.170 
the sheer number of cells that must be
targeted<00:02:58.139> and<00:02:58.290> destroyed<00:02:59.040> in<00:02:59.310> lymphomas<00:03:00.150> and

00:03:00.170 --> 00:03:00.180 
targeted and destroyed in lymphomas and

00:03:00.180 --> 00:03:01.220 
targeted and destroyed in lymphomas and
leukemias

00:03:01.220 --> 00:03:01.230 
leukemias

00:03:01.230 --> 00:03:03.800 
leukemias
for<00:03:02.129> these<00:03:02.250> reasons<00:03:02.730> most<00:03:03.000> patients<00:03:03.540> do<00:03:03.780> not

00:03:03.800 --> 00:03:03.810 
for these reasons most patients do not

00:03:03.810 --> 00:03:06.319 
for these reasons most patients do not
attain<00:03:04.409> complete<00:03:04.980> response<00:03:05.519> with<00:03:05.909> treatment

00:03:06.319 --> 00:03:06.329 
attain complete response with treatment

00:03:06.329 --> 00:03:09.429 
attain complete response with treatment
of<00:03:06.480> Rituxan<00:03:07.049> alone<00:03:07.370> this<00:03:08.370> is<00:03:08.430> where<00:03:08.790> radio

00:03:09.429 --> 00:03:09.439 
of Rituxan alone this is where radio

00:03:09.439 --> 00:03:11.479 
of Rituxan alone this is where radio
immunotherapy<00:03:10.439> allows<00:03:10.919> for<00:03:11.250> further

00:03:11.479 --> 00:03:11.489 
immunotherapy allows for further

00:03:11.489 --> 00:03:15.759 
immunotherapy allows for further
treatment<00:03:11.939> options<00:03:13.489> Radio<00:03:14.510> immunotherapy

00:03:15.759 --> 00:03:15.769 
treatment options Radio immunotherapy

00:03:15.769 --> 00:03:18.289 
treatment options Radio immunotherapy
immunotherapy<00:03:16.769> that<00:03:16.799> uses<00:03:17.400> very<00:03:17.699> focused

00:03:18.289 --> 00:03:18.299 
immunotherapy that uses very focused

00:03:18.299 --> 00:03:20.479 
immunotherapy that uses very focused
high<00:03:18.629> doses<00:03:19.139> of<00:03:19.290> radiation<00:03:19.319> to<00:03:20.159> further

00:03:20.479 --> 00:03:20.489 
high doses of radiation to further

00:03:20.489 --> 00:03:22.089 
high doses of radiation to further
target<00:03:21.090> cells

00:03:22.089 --> 00:03:22.099 
target cells

00:03:22.099 --> 00:03:25.460 
target cells
Zebulon<00:03:23.099> is<00:03:23.430> the<00:03:23.669> same<00:03:23.940> monoclonal<00:03:24.720> antibody

00:03:25.460 --> 00:03:25.470 
Zebulon is the same monoclonal antibody

00:03:25.470 --> 00:03:28.550 
Zebulon is the same monoclonal antibody
as<00:03:25.739> Rituxan<00:03:26.579> which<00:03:26.970> recognizes<00:03:27.780> and<00:03:27.959> binds<00:03:28.199> to

00:03:28.550 --> 00:03:28.560 
as Rituxan which recognizes and binds to

00:03:28.560 --> 00:03:31.879 
as Rituxan which recognizes and binds to
the<00:03:28.650> cd20<00:03:29.280> receptor<00:03:29.760> by<00:03:30.720> radio<00:03:31.139> labeling<00:03:31.680> this

00:03:31.879 --> 00:03:31.889 
the cd20 receptor by radio labeling this

00:03:31.889 --> 00:03:34.490 
the cd20 receptor by radio labeling this
antibody<00:03:32.340> Zebulon<00:03:33.329> with<00:03:33.540> the<00:03:33.720> beta<00:03:34.049> emitter

00:03:34.490 --> 00:03:34.500 
antibody Zebulon with the beta emitter

00:03:34.500 --> 00:03:37.879 
antibody Zebulon with the beta emitter
idiom<00:03:35.220> 90<00:03:35.609> it<00:03:35.790> binds<00:03:36.299> to<00:03:36.540> the<00:03:36.780> cd20<00:03:37.379> receptor

00:03:37.879 --> 00:03:37.889 
idiom 90 it binds to the cd20 receptor

00:03:37.889 --> 00:03:40.309 
idiom 90 it binds to the cd20 receptor
targeting<00:03:38.489> both<00:03:38.699> the<00:03:38.970> bound<00:03:39.359> lymphoma<00:03:40.079> cell

00:03:40.309 --> 00:03:40.319 
targeting both the bound lymphoma cell

00:03:40.319 --> 00:03:43.939 
targeting both the bound lymphoma cell
and<00:03:40.620> adjacent<00:03:41.459> cells<00:03:41.840> the<00:03:42.840> path<00:03:43.079> length<00:03:43.560> for

00:03:43.939 --> 00:03:43.949 
and adjacent cells the path length for

00:03:43.949 --> 00:03:46.159 
and adjacent cells the path length for
the<00:03:44.009> beta<00:03:44.220> emitter<00:03:44.579> iridium<00:03:45.239> 90<00:03:45.599> is<00:03:45.810> 5

00:03:46.159 --> 00:03:46.169 
the beta emitter iridium 90 is 5

00:03:46.169 --> 00:03:48.830 
the beta emitter iridium 90 is 5
millimeters<00:03:46.949> so<00:03:47.459> all<00:03:47.729> cells<00:03:48.150> within<00:03:48.540> this

00:03:48.830 --> 00:03:48.840 
millimeters so all cells within this

00:03:48.840 --> 00:03:51.920 
millimeters so all cells within this
range<00:03:49.139> are<00:03:49.470> also<00:03:49.709> targeted<00:03:50.400> not<00:03:51.359> only<00:03:51.720> does

00:03:51.920 --> 00:03:51.930 
range are also targeted not only does

00:03:51.930 --> 00:03:54.140 
range are also targeted not only does
the<00:03:52.109> radiation<00:03:52.409> destroy<00:03:53.159> the<00:03:53.400> b-cell<00:03:53.849> to

00:03:54.140 --> 00:03:54.150 
the radiation destroy the b-cell to

00:03:54.150 --> 00:03:56.210 
the radiation destroy the b-cell to
which<00:03:54.299> the<00:03:54.509> antibody<00:03:54.959> is<00:03:55.169> bound<00:03:55.439> but<00:03:55.919> it<00:03:56.040> also

00:03:56.210 --> 00:03:56.220 
which the antibody is bound but it also

00:03:56.220 --> 00:03:58.699 
which the antibody is bound but it also
damages<00:03:56.909> the<00:03:57.239> surrounding<00:03:57.750> cells<00:03:57.989> in<00:03:58.409> what<00:03:58.590> is

00:03:58.699 --> 00:03:58.709 
damages the surrounding cells in what is

00:03:58.709 --> 00:04:01.309 
damages the surrounding cells in what is
called<00:03:59.009> the<00:03:59.280> cross<00:03:59.639> fire<00:03:59.970> or<00:04:00.319> bystander

00:04:01.309 --> 00:04:01.319 
called the cross fire or bystander

00:04:01.319 --> 00:04:04.879 
called the cross fire or bystander
effect<00:04:02.449> Rituxan<00:04:03.479> pretreatment<00:04:04.229> at<00:04:04.379> 7<00:04:04.709> days

00:04:04.879 --> 00:04:04.889 
effect Rituxan pretreatment at 7 days

00:04:04.889 --> 00:04:07.399 
effect Rituxan pretreatment at 7 days
then<00:04:05.310> 4<00:04:05.639> hours<00:04:05.669> prior<00:04:06.389> to<00:04:06.449> Zebulon<00:04:07.259> is

00:04:07.399 --> 00:04:07.409 
then 4 hours prior to Zebulon is

00:04:07.409 --> 00:04:09.860 
then 4 hours prior to Zebulon is
necessary<00:04:08.099> to<00:04:08.340> clear<00:04:08.579> circulating<00:04:09.359> B<00:04:09.569> cells

00:04:09.860 --> 00:04:09.870 
necessary to clear circulating B cells

00:04:09.870 --> 00:04:12.619 
necessary to clear circulating B cells
and<00:04:10.109> other<00:04:10.620> nonspecific<00:04:11.609> binding<00:04:11.819> partners

00:04:12.619 --> 00:04:12.629 
and other nonspecific binding partners

00:04:12.629 --> 00:04:15.110 
and other nonspecific binding partners
in<00:04:12.840> the<00:04:12.930> body<00:04:13.109> allowing<00:04:13.979> Zebulon<00:04:14.609> to<00:04:14.759> deliver

00:04:15.110 --> 00:04:15.120 
in the body allowing Zebulon to deliver

00:04:15.120 --> 00:04:17.509 
in the body allowing Zebulon to deliver
radiation<00:04:15.299> more<00:04:15.930> specifically<00:04:16.590> to<00:04:16.889> lymphoma

00:04:17.509 --> 00:04:17.519 
radiation more specifically to lymphoma

00:04:17.519 --> 00:04:20.210 
radiation more specifically to lymphoma
cells<00:04:17.780> this<00:04:18.780> combined<00:04:19.320> approach<00:04:19.650> has<00:04:20.009> been

00:04:20.210 --> 00:04:20.220 
cells this combined approach has been

00:04:20.220 --> 00:04:22.730 
cells this combined approach has been
shown<00:04:20.549> in<00:04:20.789> studies<00:04:21.180> to<00:04:21.209> improve<00:04:21.570> the<00:04:22.109> overall

00:04:22.730 --> 00:04:22.740 
shown in studies to improve the overall

00:04:22.740 --> 00:04:26.029 
shown in studies to improve the overall
response<00:04:23.279> rate<00:04:23.400> for<00:04:23.820> therapy<00:04:24.210> from<00:04:24.510> 56%<00:04:25.260> using

00:04:26.029 --> 00:04:26.039 
response rate for therapy from 56% using

00:04:26.039 --> 00:04:27.440 
response rate for therapy from 56% using
Rituxan<00:04:26.580> only

00:04:27.440 --> 00:04:27.450 
Rituxan only

00:04:27.450 --> 00:04:30.380 
Rituxan only
to<00:04:27.540> 80%<00:04:28.380> with<00:04:28.440> use<00:04:28.830> of<00:04:29.070> Rituxan<00:04:29.700> pretreatment

00:04:30.380 --> 00:04:30.390 
to 80% with use of Rituxan pretreatment

00:04:30.390 --> 00:04:32.660 
to 80% with use of Rituxan pretreatment
with<00:04:30.510> idiom<00:04:31.170> 90<00:04:31.590> Zeppelin<00:04:32.220> radio

00:04:32.660 --> 00:04:32.670 
with idiom 90 Zeppelin radio

00:04:32.670 --> 00:04:35.570 
with idiom 90 Zeppelin radio
immunotherapy

